DMAC Logo

DiaMedica Therapeutics Inc. (DMAC) 

NASDAQ
Market Cap
$233.47M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
67 of 968
Rank in Industry
50 of 556

Largest Insider Buys in Sector

DMAC Stock Price History Chart

DMAC Stock Performance

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Insider Activity of DiaMedica Therapeutics Inc.

Over the last 12 months, insiders at DiaMedica Therapeutics Inc. have bought $6M and sold $0 worth of DiaMedica Therapeutics Inc. stock.

On average, over the past 5 years, insiders at DiaMedica Therapeutics Inc. have bought $3.41M and sold $3.53M worth of stock each year.

Highest buying activity among insiders over the last 12 months: STAHLBERG JAN (10 percent owner) — $3M. Von Koch Thomas (10 percent owner) — $3M.

The last purchase of 1,200,000 shares for transaction amount of $3M was made by Von Koch Thomas (10 percent owner) on 2024‑06‑28.

List of Insider Buy and Sell Transactions, DiaMedica Therapeutics Inc.

2024-06-28Purchase10 percent owner
1.2M
2.6697%
$2.50$3M0.00%
2024-06-28Purchase10 percent owner
1.2M
2.6697%
$2.50$3M0.00%
2023-11-16PurchaseChief Business Officer
20,000
0.0542%
$2.46$49,200+23.43%
2023-06-23Purchase10 percent owner
1.47M
4.4481%
$3.40$5M-33.18%
2023-06-23PurchaseChief Business Officer
38,364
0.1334%
$3.91$150,003-33.18%
2023-06-23Purchasedirector
65,000
0.2261%
$3.91$254,150-33.18%
2023-06-23Purchasedirector
38,363
0.1334%
$3.91$149,999-33.18%
2023-06-23PurchasePresident and CEO
12,787
0.0445%
$3.91$49,997-33.18%
2023-06-23PurchaseCFO and Secretary
10,000
0.0348%
$3.91$39,100-33.18%
2023-06-23Purchasedirector
12,787
0.0445%
$3.91$49,997-33.18%
2023-04-10PurchaseChief Business Officer
468,750
1.8065%
$1.60$750,000+79.62%
2022-12-09Purchasedirector
37,079
0.1402%
$1.43$53,023+57.34%
2022-12-08Purchasedirector
20,000
0.0735%
$1.40$28,000+55.90%
2022-12-07Purchasedirector
22,574
0.086%
$1.40$31,604+61.15%
2022-12-06Purchasedirector
2,300
0.0083%
$1.35$3,105+57.39%
2022-12-05Purchasedirector
35,000
0.14%
$1.39$48,493+69.08%
2022-12-02Saledirector
2.86M
9.0121%
$1.24$3.53M+47.97%
2022-12-02Purchasedirector
2.86M
9.0121%
$1.24$3.53M+47.97%
2022-12-01Purchasedirector
46,952
0.1775%
$1.20$56,334+82.08%
2022-11-30Purchasedirector
2,970
0.0112%
$1.19$3,534+82.77%

Insider Historical Profitability

17.55%
Von Koch Thomas10 percent owner
5526435
12.9241%
$5.4631+7.4%
STAHLBERG JAN10 percent owner
5221608
12.2113%
$5.4610
TomEnterprise AB
2855827
6.6786%
$5.4610+16.67%
Wambeke David J.Chief Business Officer
527114
1.2327%
$5.4630+23.22%
Giuffre Randall Michaeldirector
360355
0.8427%
$5.46100+49.77%
Pilnik Richard D.director
248245
0.5805%
$5.4670+16.67%
Pauls Dietrich JohnPresident and CEO
68591
0.1604%
$5.4650+13.96%
Burroughs Amy L.director
44950
0.1051%
$5.4610<0.0001%
ALCORN HARRY W JRSVP, Clinical Operations
43582
0.1019%
$5.4650<0.0001%
Kellen ScottCFO and Secretary
32290
0.0755%
$5.4660+15.37%
Semba Charles Paulingdirector
29943
0.07%
$5.4610<0.0001%
Xiao Zhenyu
7100
0.0166%
$5.4610<0.0001%
Parsons James T.director
6100
0.0143%
$5.4610<0.0001%
Verdoorn Todd A.Chief Scientific Officer
2000
0.0047%
$5.4610<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$2.81M2.671.01M+26.35%+$585,442.28<0.0001
Leon G. Cooperman$2.45M2.33883,6230%+$00.1
First Manhattan Co.$2.35M2.24850,038+640.81%+$2.04M0.01
Paragon Associates Paragon Associates Ii Joint Venture$1.39M1.32500,0000%+$02.47
Geode Capital Management$662,841.000.63239,235+9.35%+$56,679.58<0.0001
Bleichroeder Lp$615,818.000.59222,3170%+$00.16
Susquehanna International Group$579,850.000.55209,332+657.93%+$503,345.32<0.01
Northern Trust$354,059.000.34127,819-4.35%-$16,104.80<0.0001
Aristides Capital$294,542.000.28106,3330%+$00.13
BlackRock$286,334.000.27103,370-1.3%-$3,772.73<0.0001
Morgan Stanley$253,657.000.2491,573-24.32%-$81,498.87<0.0001
State Street$184,562.000.1866,6290%+$0<0.0001
Catalyst Financial Partners Llc$94,294.000.136,2670%+$00.02
BNY Mellon$66,479.000.0624,000-29.89%-$28,344.98<0.0001
Citadel Advisors LLC$66,535.000.0624,020+5.75%+$3,614.83<0.0001
Stonebridge Capital Advisors Llc$55,400.000.0520,0000%+$00.01
Dimensional Fund Advisors$46,977.000.0516,9590%+$0<0.0001
Jane Street Capital$42,209.000.0415,238-35.87%-$23,608.56<0.0001
Charles Schwab$36,705.000.0413,2510%+$0<0.0001
Massmutual Trust Co Fsb Adv$13,362.000.014,8240%+$0<0.0001
U.S. Bancorp$12,008.000.014,3350%+$0<0.0001
Tower Research Capital$7,468.000.012,696-62.88%-$12,653.50<0.0001
UBS$5,335.000.011,926New+$5,335.00<0.0001
Advisor Group Holdings Inc$2,770.00<0.011,0000%+$0<0.0001
Legend Financial Advisors Inc$2,770.00<0.011,0000%+$0<0.01
Royal Bank of Canada$2,000.00<0.01845-21.9%-$560.95<0.0001
Toronto-Dominion Bank$66.00<0.01240%+$0<0.0001
Wells Fargo$485.00<0.01175+1.74%+$8.31<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.